Search
forLearn
5 / 26 resultslearn Minoxidil
An essential vasodilator with some anti-androgenic effects, has excellent safety record
learn Fluridil
a topical anti-androgen with less systemic involvement
learn Low Level Laser Therapy
laser therapy for anti-inflammatory and likely insignificant hair regrowth effects
learn RU58841
a potent but unapproved and potentially problematic topical anti-androgen
Research
5 / 1000+ results
research Use of a Healthcare Claims Database for Post-Marketing Safety Assessments of Eribulin in Japan: A Comparative Assessment with a Prospective Post-Marketing Surveillance Study
Healthcare claims databases can help monitor drug safety, but may report adverse events differently than direct surveillance.
research Safety First: A Comprehensive Review of Nutritional Supplements for Hair Loss in Breast Cancer Patients
Consult an oncologist before using supplements for hair loss during breast cancer treatment.
research Real-World Efficacy and Safety of Cuticapil Stem Hair Serum as an Add-On to Minoxidil in Androgenetic Alopecia: A Prospective Observational Study
Cuticapil Stem Hair Serum improves hair growth and reduces shedding when added to minoxidil.
research Clinical Efficacy and Safety of Low-Dose Oral Minoxidil Versus Topical Solution in the Improvement of Androgenetic Alopecia: A Randomized Controlled Trial
Oral minoxidil is more convenient but topical minoxidil improves hair density better.
research Comparative Analysis of Various Hair Peptide Serums in Managing Telogen Effluvium in Females: Efficacy, Safety, and Patient Satisfaction
The cytokine and peptide serum was most effective in reducing hair loss and improving hair growth.
Community Join
5 / 835 resultscommunity GT20029 China Phase II Trial For AGA Reached Primary Endpoint
The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.
community The story of RU58841/ PSK3841
RU58841, a potential hair loss treatment, was not commercialized due to marketability issues and lack of long-term safety data. Concerns about its formulation and delivery methods further complicate its use.
community Phase II for Technoderma Therepeutic's TDM-105795 set to begin in April tentatively
Phase II for TDM-105795 for Androgenic Alopecia is set to begin in April 2023. The study aims to evaluate the efficacy and safety of TDM-105795 in male subjects.
community Evidenced Based Meta-Analyses and Systemic Reviews of Androgenic Alopecia and Treatments
Evidence-based treatments for androgenic alopecia, such as minoxidil, finasteride, low-level laser light therapy, dutasteride, platelet-rich plasma, and topical ketoconazole. It discusses the efficacy, safety, and mechanism of action of these treatments, as well as future developments in understanding this polygenic condition.
community Why is nobody talking about the new study results for Pyrilutamide??
Pyrilutamide shows promising hair growth results, but skepticism exists due to potential biases and lack of blinding in the study. Concerns about side effects and legitimacy of the product persist, with comparisons to finasteride and discussions on post-finasteride syndrome.